Exavir Therapeutics announces the publication of preclinical data for the ultra-long-acting integrase inhibitor XVIR-110 in Nature Communications, affirming its unique pharmacokinetic profile and potential as a best-in-class yearly antiretroviral
June 08, 2021 07:00 ET | Exavir Therapeutics
With a single administration, XVIR-110, a nano-formulated prodrug integrase inhibitor, provided year-long plasma drug levels sufficient for HIV treatment and prophylaxis in animal models Studies...
Americans Need COVID Treatment NOW, States the Association of American Physicians & Surgeons (AAPS)
October 20, 2020 15:55 ET | Association of American Physicians and Surgeons
TUCSON, Ariz., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Americans, even one who is as carefully shielded as the President of the United States, continue to be infected with COVID-19. The Association of...
CidaraLogo (1).jpg
Cidara Therapeutics to Present at Two Upcoming Investor Conferences
September 24, 2018 16:05 ET | Cidara Therapeutics, Inc.
SAN DIEGO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that...
CidaraLogo (1).jpg
Cidara Provides Corporate Update and Reports Second Quarter 2018 Financial Results
August 08, 2018 16:30 ET | Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
CidaraLogo (1).jpg
Cidara Provides Corporate Update and Reports First Quarter 2018 Financial Results
May 10, 2018 16:05 ET | Cidara Therapeutics, Inc.
SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...